Chiasma to Report Fourth Quarter 2020 Results on March 4
Chiasma, Inc. (NASDAQ: CHMA) announced a conference call and live audio webcast on March 4, 2021, at 5:00 PM ET, to discuss its financial results for the quarter and year ended December 31, 2020, along with a business update. Domestic participants can join the call at 877-407-4018 or international at 201-689-8471. The conference ID is 13715763. A webcast will be accessible at this link and will be archived on Chiasma’s website.
- None.
- None.
Company to host conference call and webcast at 5:00 p.m. ET
NEEDHAM, Maine, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, March 4, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter and year ended December 31, 2020 and to provide a business update.
Conference Call Details
Thursday, March 4th @ 5:00 pm Eastern Time
| Domestic: | 877-407-4018 |
| International: | 201-689-8471 |
| Conference ID: | 13715763 |
| Webcast: | http://public.viavid.com/index.php?id=143291 |
A live audio webcast of the call may also be accessed under "Events & Presentations" on the News & Investors section of the Company's website, https://ir.chiasma.com/events-presentations. An archived replay of the webcast will be available on the Company’s website approximately two hours after the event. The archived webcast will be available for one year.
About Chiasma
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at www.chiasma.com.
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
617-775-5956
arr@lifesciadvisors.com
Media Relations:
Patrick Bursey
LifeSci Communications
646-876-4932
pbursey@lifescicomms.com
FAQ
What is the date and time of Chiasma's conference call?
How can I access the Chiasma conference call?
What topics will be discussed in Chiasma's conference call?
Is there a webcast available for Chiasma's conference call?
What is the conference ID for Chiasma's call?
